Bristol Myers Squibb Announces ZENBEXUSTM (iberdomide) in Combination with Daratumumab and Dexamethasone (ZDd) Demonstrates Superior Progression-Free Survival vs. Standard of Care in Relapsed and Refractory Multiple Myeloma in Phase 3...

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

• ZENBEXUS is an effective oral treatment option that can be easily used in diverse care settings, including community settings.

  60% confidence

• The safety profile of ZENBEXUS in combination with standard therapies remained consistent with previously reported safety findings from the study.

  60% confidence

• ZDd demonstrated a statistically significant improvement in PFS vs DVd in EXCALIBER-RRMM: median PFS 42 vs 20 months, HR 0.49, p<0.000001, a 51% reduction in risk of progression or death.

  60% confidence

• EXCALIBER-RRMM results reinforce the clinical value of ZENBEXUS with daratumumab and dexamethasone; MRD negativity benefit translated into meaningful PFS improvement.

  60% confidence

Cited in these Via News reports

• Cancer-drug approvals are stacking up in Q4 2026, but the AI promises and Summit's cash needs are what to check →
• Oncology's Busy Autumn: A Cash-Burning Drugmaker Awaits Its Verdict While AI Promises Faster Medicines →
• Oncology's Next Wave Meets Its Test: Summit's Nov. 14 Ivonescimab Decision, a Record Loss, and AI Claims That Are Still Forecasts →
• Oncology's Q4 Decision Window: Three Dated Catalysts, One Already Delivered, and a Sector Splitting Between Cash-Rich and Cash-Careful →
• Oncology's Three Bets: New Drug Types, AI-Built Medicines and a $5.8 Billion Care Deal, and the Cash Behind One Closely Watched Drug →